Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Controversies in Proteomics

This article was originally published in Start Up

Executive Summary

A Lancet paper published two years ago detailing a promising but highly novel approach to detecting ovarian cancer, one of the deadliest cancers, continues to be the subject of great controversy in cancer circles. The test uses proteomic pattern profiling to detect the cancer, with a more than 95% accuracy in early studies, but no one knows what the patterns are made of. The NCI and two large reference labs are pushing ahead to get the test into the clinic, on the premise that as long as it is so good at detecting cancer, a lack of understanding of the underlying biochemistry isn't an insurmountable hurdle to acceptance.

You may also be interested in...



Molecular Dx as a Hot Spot

Although it's still a small portion of the $30-plus billion diagnostic services and test supplies business, molecular diagnostics is on disproportionately rapid growth curve. Some estimate its revenue growth at 25% a year compared to the overall industry average of 3-5%. Reimbursement is improving and robust new tests are emerging, slowly but steadily.

Molecular Dx as a Hot Spot

Although it's still a small portion of the $30-plus billion diagnostic services and test supplies business, molecular diagnostics is on disproportionately rapid growth curve. Some estimate its revenue growth at 25% a year compared to the overall industry average of 3-5%. Reimbursement is improving and robust new tests are emerging, slowly but steadily.

Predicant Biosciences Inc.

Among proteomics experts, however, a split has emerged between those who believe protein profiling patterns, rather than proteins themselves, are important indicators of disease, and those who believe that the proteins need to be identified before they can be useful clinically. Predicant Biosciences is taking the side of the former group, and, supported by a top-notch group of scientists and venture capitalists, is developing an integrated system it hopes will move the field forward.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel